Instrument Inactif

Communiqués TapImmune Inc. Other OTC

Actions

US8760333091

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

15/05	Marker Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
30/04	MARKER THERAPEUTICS, INC. : Ladenburg Thalmann toujours positif	ZM

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates	15/05	AQ
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	08/04	AQ
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	25/03	AQ
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	22/03	AQ
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03	AQ
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	22/01	AQ
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01	AQ
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	21/12	AQ
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	11/12	AQ
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	09/11	AQ
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse	11/09/23	AQ
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	30/08/23	AQ
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies	17/08/23	NE
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	14/08/23	AQ
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program	07/08/23	AQ
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023	26/07/23	AQ
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients	10/07/23	AQ
Marker Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K	30/06/23	PU
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration	26/06/23	AQ
"Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations":- IPA, MRKR, PRAX , RMED	21/06/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués TapImmune Inc. Other OTC

Actions

US8760333091

Communiqués

Filtres